Comorbidity of Cervical Spondylogenic Myelopathy and Amyotrophic Lateral Sclerosis: When Electromyography Makes the Difference in Diagnosis

2020 ◽  
pp. 1-4
Author(s):  
Maria Claudia Torrieri ◽  
Matteo Monticelli ◽  
Rosario Vasta ◽  
Fabio Cofano ◽  
Marco Ajello ◽  
...  

Cervical spondylogenic myelopathy (CSM) represents a common differential diagnosis for spinal onset Amyotrophic Lateral Sclerosis (ALS). Identifying occurrence of ALS in patients with CSM may be challenging. We evaluated the accuracy of Awaji criteria in the diagnosis of ALS in a cohort of patients with CSM. We screened all patients attending Turin ALS Center during the 2006–2018 period. We selected only patients for whom cervical cord MRI showed radiological signs of CSM. All patients underwent electromyography (EMG), and Awaji criteria were used for diagnosis of clinically probable ALS. All patients were followed up clinically for at least 6 months, and ALS diagnosis was eventually confirmed according to El-Escorial revised criteria, based on disease progression. Of 2,059 patients screened, in 42 cases, MRI showed signs of CSM; CSM incidence and prevalence risks were 0.16 and 2.04%, respectively. Based on clinical progression, 72.7% of patients were diagnosed as CSM and 27.3% as CSM + ALS. At EMG 6 (18.2%) patients fulfilled the criteria for ALS, 5 of them (83.3%) during clinical follow-up were diagnosed as clinical definite ALS + CSM. Accuracy of Awaji criteria in diagnosing ALS was good (AUC = 0.757, <i>p</i> = 0.03). Sensitivity and specificity of Awaji criteria were, respectively, 55.6 and 95.8%. Positive predictive value was 83.3%, while negative predictive value was 85.2%. CSM-ALS comorbidity is a relatively common problem in clinical practice. To better choose patients who could benefit from surgery, EMG should be performed in CSM patients, due to its good accuracy in recognizing ALS.

2015 ◽  
Vol 22 (10) ◽  
pp. 1385-1390 ◽  
Author(s):  
F. Patin ◽  
P. Corcia ◽  
B. Madji Hounoum ◽  
C. Veyrat-Durebex ◽  
E. Respaud ◽  
...  

1966 ◽  
Vol 83 (1) ◽  
pp. 54-73 ◽  
Author(s):  
DWAYNE REED ◽  
CHRIS PLATO ◽  
TERESITA ELIZAN ◽  
LEONARD T. KURLAND

2019 ◽  
Vol 6 (6) ◽  
pp. e631 ◽  
Author(s):  
Marlena Wosiski-Kuhn ◽  
Mac Robinson ◽  
Jane Strupe ◽  
Phonepasong Arounleut ◽  
Matthew Martin ◽  
...  

ObjectiveTo test the hypothesis that patients with amyotrophic lateral sclerosis (ALS) inheriting the common interleukin 6 receptor (IL6R) coding variant (Asp358Ala, rs2228145, C allele) have associated increases in interleukin 6 (IL6) and IL6R levels in serum and CSF and faster disease progression than noncarriers.MethodsAn observational, case-control study of paired serum and CSF of 47 patients with ALS, 46 healthy, and 23 neurologic disease controls from the Northeastern ALS Consortium Biofluid Repository (cohort 1) was performed to determine serum levels of IL6, sIL6R, and soluble glycoprotein 130 and compared across groups and IL6R genotype. Clinical data regarding disease progression from a separate cohort of 35 patients with ALS from the Wake Forest ALS Center (cohort 2) were used to determine change in ALSFRS-R scores by genotype.ResultsPatients with ALS had increased CSF IL6 levels compared with healthy (p < 0.001) and neurologic (p = 0.021) controls. Patients with ALS also had increased serum IL6 compared with healthy (p = 0.040) but not neurologic controls. Additive allelic increases in serum IL6R were observed in all groups (average increase of 52% with the presence of the IL6R C allele; p < 0.001). However, only subjects with ALS had significantly increased CSF sIL6R levels compared with controls (p < 0.001). When compared across genotypes, only patients with ALS inheriting the IL6R C allele exhibit increased CSF IL6. ALSFRS-R scores decreased more in patients with ALS with the IL6R C allele than in those without (p = 0.019).ConclusionsTheses results suggest that for individuals inheriting the IL6R C allele, the cytokine exerts a disease- and location-specific role in ALS. Follow-up, prospective studies are necessary, as this subgroup of patients may be identified as ideally responsive to IL6 receptor–blocking therapies.


2018 ◽  
Vol 10 (4) ◽  
pp. 139-144 ◽  
Author(s):  
T. M. Alekseeva ◽  
N. V. Skripchenko ◽  
S. V. Lobzin ◽  
V. S. Demeshonok ◽  
E. A. Yurkina ◽  
...  

We described a case of amyotrophic lateral sclerosis (ALS) with comorbid HIV infection. The diagnosis was confirmed by genetic tests. The difficulty of the differential diagnosis between amyotrophic lateral sclerosis and HIV-associated ALS syndrome is discussed.


2021 ◽  
Author(s):  
Renato Puccioni Sohler ◽  
Gabriel Pinto Mendonça ◽  
Rodrigo Cesar Carvalho Freitas ◽  
José Roberto Ribas

Background: amyotrophic lateral sclerosis (ALS) is a motor neuron degenerative disease with high mortality and few therapies. One of these is riluzole, inspite of uncertainty effectiveness. Objective: the aim of this study was to evaluate the survival rate associated with the use of this medication in the treatment of ALS. Methods: The study was based on a narrative review of the scientific articles that used randomized controled trials with riluzole for ALS. We selected articles published in english during the period of January 1th, 2000 to December 31th, 2020. The MeSH terms “amyotrophic lateral sclerosis” or “motor neuron disease” and “riluzole” or “rilutek” were used in Pubmed and Lilacs databases. Studies that used only patients with advanced stage ALS were excluded. The t-Student test between sample means was applied to determine the significance of the difference between the survival time (years) of the riluzole and placebo treatment, for a 95% confidence level. Results: through the search, four articles were obtained (Table 1). Conclusion: Data analysis showed that riluzole is only effective in the first year. From the second onward, it does not exceed the results of the placebo.


2020 ◽  
Vol 91 (8) ◽  
pp. 867-875 ◽  
Author(s):  
Mark R Janse van Mantgem ◽  
Ruben P A van Eijk ◽  
Hannelore K van der Burgh ◽  
Harold H G Tan ◽  
Henk-Jan Westeneng ◽  
...  

ObjectiveTo determine the prevalence and prognostic value of weight loss (WL) prior to diagnosis in patients with amyotrophic lateral sclerosis (ALS).MethodsWe enrolled patients diagnosed with ALS between 2010 and 2018 in a population-based setting. At diagnosis, detailed information was obtained regarding the patient’s disease characteristics, anthropological changes, ALS-related genotypes and cognitive functioning. Complete survival data were obtained. Cox proportional hazard models were used to assess the association between WL and the risk of death during follow-up.ResultsThe data set comprised 2420 patients of whom 67.5% reported WL at diagnosis. WL occurred in 71.8% of the bulbar-onset and in 64.2% of the spinal-onset patients; the mean loss of body weight was 6.9% (95% CI 6.8 to 6.9) and 5.5% (95% CI 5.5 to 5.6), respectively (p<0.001). WL occurred in 35.1% of the patients without any symptom of dysphagia. WL is a strong independent predictor of survival, with a dose response relationship between the amount of WL and the risk of death: the risk of death during follow-up increased by 23% for every 10% increase in WL relative to body weight (HR 1.23, 95% CI 1.13 to 1.51, p<0.001).ConclusionsThis population-based study shows that two-thirds of the patients with ALS have WL at diagnosis, which also occurs independent of dysphagia, and is related to survival. Our results suggest that WL is a multifactorial process that may differ from patient to patient. Gaining further insight in its underlying factors could prove essential for future therapeutic measures.


Sign in / Sign up

Export Citation Format

Share Document